Crestwood Advisors Group’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,046
Closed -$614K 780
2025
Q4
$614K Buy
6,046
+906
+18% +$72.8K 0.01% 352
2025
Q3
$281K Sell
5,140
-9
-0.2% -$450 ﹤0.01% 479
2025
Q2
$274K Buy
5,149
+328
+7% +$16.7K ﹤0.01% 464
2025
Q1
$209K Sell
4,821
-19
-0.4% -$962 ﹤0.01% 480
2024
Q4
$272K Buy
4,840
+527
+12% +$32.8K 0.01% 401
2024
Q3
$294K Buy
+4,313
New +$243K 0.01% 371
2024
Q2
Sell
-4,501
Closed -$311K 434
2024
Q1
$311K Hold
4,501
0.01% 345
2023
Q4
$333K Sell
4,501
-305
-6% -$20K 0.01% 316
2023
Q3
$328K Buy
+4,806
New +$408K 0.01% 286

Other funds holding EXAS

Crestwood Advisors Group's EXAS Position: Q1 2026 in Review

Crestwood Advisors Group sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 6,046 shares — an estimated $614K sold.

Crestwood Advisors Group first reported a position in EXAS in Q3 2023 and held it in 9 quarters. The position peaked at $614K in Q4 2025. 6 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Crestwood Advisors Group reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Crestwood Advisors Group sold 6,046 Exact Sciences shares in Q1 2026, an estimated $614K.
  • Crestwood Advisors Group first reported a position in Exact Sciences in Q3 2023 and held it in 9 quarters.
  • Crestwood Advisors Group's Exact Sciences position peaked at $614K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Crestwood Advisors Group's 13F filing for Q1 2026, filed 5 May 2026.